
Index

- acceptance criteria
 - assay development 22–3
 - Cyflex technology 204–7
 - enzyme-linked immunospot assays 142–3, 170, 187–9
 - ex vivo* stimulation assays 46
 - flow cytometry 100–1
 - neutralization bioassays 235–6
 - peripheral blood mononuclear cells 34
- accountability cytometry 111
- accuracy 138–9
- acid citrate dextrose (ACD) 241–2
- acquired immunodeficiency syndrome
 - see* HIV/AIDS
- actinomycin D-mannitol 212, 218–19
- activation markers 74–5
- ADAs *see* anti-drug antibodies (ADAs)
- adenosine triphosphate (ATP) 194, 195–7, 205–6
- annexin V 79
- antibody-coated plates 168, 187
- anticoagulants
 - endpoint assays 241–2
 - ex vivo* stimulation assays 40–1, 43
 - flow cytometry 76
 - peripheral blood mononuclear cells 30–1, 32
- anti-drug antibodies (ADAs) 209–10
- antigen presenting cells (APCs) 140
- antigen-specific T cell assays 12, 26–7
- APCs *see* antigen presenting cells (APCs)
- apoptosis 76, 79–81
- assay controls
 - definition 27
 - ex vivo* stimulation assays 40
 - neutralization bioassays 211, 215, 217, 222, 235
- assay format 3
- ATP *see* adenosine triphosphate (ATP)
- automated screening assays 278
- binding antibodies 258–9
- biomarker scoring 62–4, 67, 69, 279–80
- biotin labeling 51, 60
- B-lymphocytes 193–4
- calibration curves 205
- capture antibody-coated plates 168, 187
- CBA *see* cytokine bead arrays (CBA)
- CD3 78, 88–92, 95–100

- CD4
 Cylex technology 194–6, 201–2, 205–6
 flow cytometry 78
 good laboratory practice 279
 HIV/AIDS 240, 247–52, 255, 267
 immunohistochemistry 69
- CD8
 flow cytometry 78
 good laboratory practice 279
 HIV/AIDS 240, 248, 250–2, 255, 267
- CD19 78, 194–6, 198–9, 201, 205–6
- CD25 74–5, 86, 93, 95–7, 100–3
- CD31 50
- CD45 75, 78
- CD69 74–5
- CEF peptides 134, 137
- cell banking 2–3
- cell cycle analysis 78–9
- cell density 29, 153, 154–5, 160, 177–9
- cell passage number 233
- CFSE labeled proteins 255
- chemokine receptors (CKR) 75
- circulating tumor cells (CTCs) 12
- CKR *see* chemokine receptors (CKR)
- CLA *see* cutaneous lymphocyte antigen (CLA)
- coefficient of variation, definition 13
- combinatorial chemistry 277–8
- consistency controls 211–12, 215, 217, 219–21
- control analytes 12
- control stability 17–18
- CPA *see* cytokine protein arrays (CPA)
- critical reagents 3, 19, 218–19, 234
- Crohn's disease 58
- cryopreservation *see* freeze/thaw procedures
- CTCs *see* circulating tumor cells (CTCs)
- culture time 177, 234
- cutaneous lymphocyte antigen (CLA)
 86, 88–95, 96–103
- cut-off
 assay development 7, 23
 neutralization bioassays 213–14, 215, 231–2
- Cylex technology
 acceptance criteria 204–7
 assay plates 199
 calibration curves 205
 data handling 197
 drug interference 203, 205
 lymphocyte activation capacity 193–207
 methodology 195–7
 optimization 197–8
 precision 199–203, 204
 reagents 195–7, 199
 sample handling 195, 198–200, 206–7
 specificity 203, 205
 stability 197–9
 standard curves 197
 variability 199–203, 204
- cytokine bead arrays (CBA) 130–2
- cytokine protein arrays (CPA) 130–2
- cytokine release models 38–9
- cytokine storms 279
- cytotoxic T lymphocytes (CTLs)
 250, 252
- data handling
 assay development 22
 Cylex technology 197
 definitions 12
 enzyme-linked immunospot assays 151–2, 187–9
ex vivo stimulation assays 46
 flow cytometry 78–9, 111, 118–19, 121
 immunohistochemistry assays 65–7, 68
 peripheral blood mononuclear cells 34
- dilutional linearity 225
- diurnal variations 42
- dose response curves 227–30
- drug interference
 Cylex technology 203, 205
 neutralization bioassays 216–17, 232
- dUTPase 50, 61
- early activation markers 74–5
- EDTA plasma 213–14, 241–2
- ELISA *see* enzyme-linked immunosorbent assays (ELISA)
- ELISPOT *see* enzyme-linked immunospot (ELISPOT) assays
- endpoint assays
 anticoagulants 241–2
 binding antibodies 258–9

- clinical trials 248–50
- enzyme-linked immunosorbent assays 243–4, 249
- enzyme-linked immunospot assays 252–5
- freeze/thaw procedures 242
- good laboratory practice 262–7
- HIV/AIDS 239–75
- humoral immune responses to HIV 1, 258–62
- internal/external audits 265
- laboratory programs 241–8, 262–3
- methodology 246–8
- neutralizing antibodies 259–62
- nucleic acid tests 243, 245, 249
- peptide antigen selection 257–8
- personnel training 263
- polychromatic flow cytometry 255–7
- quality assurance 265–7
- quality control 244
- reagents/equipment 264
- reporting requirements 264–5
- safety testing 243
- sample handling 242
- specimen processing 241–2
- standard operating procedures 263–6
- T cell immunogenicity 251–8
- vaccine pipeline 248–50
- variability 262, 264
- Western blot analyzes 243, 244–6, 247–9
- enzyme-linked immunosorbent assays (ELISA)
 - anti-drug antibodies 210
 - cytokines 130–2
 - endpoint assays 243–8, 249
 - ex vivo* stimulation assays 39, 42, 45
 - HIV/AIDS 243–6, 249
 - interferon 223–7, 235
 - intracellular cytokine staining 111
 - optimization 134, 135
 - regulatory bodies 129
- enzyme-linked immunospot (ELISPOT) assays
 - acceptance criteria 142–3, 170, 187–9
 - accuracy 138–9
 - assay development 12
 - assay plates 167–8, 185–7
 - cell density 153, 154–5, 160, 177–9
 - cross-titration 134, 136
 - culture time 177
 - data handling 151–2, 187–9
 - endpoint assays 252–5
 - freeze/thaw procedures 149–50, 154–66, 174–5
 - good laboratory practice 128, 266–7
 - HIV/AIDS 252–5
 - IL-5 ELISPOT assays 173–91
 - interferon- γ 131, 137, 143–4, 147–72, 173, 190, 252–3
 - interleukins 173–4, 175
 - intracellular cytokine staining 108, 111, 132, 133
 - limits of detection/quantification 140–1, 155, 160, 168–9, 187–9
 - linearity 140
 - lymphocyte activation capacity 194
 - methodology 149–52, 174–5
 - multimerized MHC molecules 133
 - optimization 134–8, 176–8
 - overview 129–30
 - parameter testing 138
 - performance comparisons 130–3
 - peripheral blood mononuclear cells 29, 133–4, 139, 148–70, 174–87, 189–90
 - polyclonal activators 148, 150, 153–70
 - precision 139, 163–6, 182–5, 190
 - protocols 150–1, 169–70
 - qualification experiments 138, 142
 - range 141
 - reagents 150–1, 152–4, 166–70, 175–6, 185–7
 - reference samples 127–46
 - regulatory bodies 127–9, 144
 - sample handling 149–50, 152–66, 178–82
 - specificity 139–40, 152–4, 175–6, 190
 - stability 162–3, 168, 178, 181
 - statistics 143–4
 - validation controls 152–66
 - variability 134–8, 142, 161–2, 163–6, 182–5, 190
 - viability assessments 180–1
- EQA *see* external quality assurance (EQA)

- ex vivo* stimulation assays
 - acceptance criteria 46
 - anticoagulants 40–1, 43
 - assay development 40–3
 - clinical testing of samples 46
 - conditions 41
 - cytokine release models 38–9
 - data handling 46
 - definitions 39–40
 - diurnal variations 42
 - freeze/thaw procedures 38
 - limits of quantification 45
 - optimization 40–3
 - precision 44–5
 - robustness 43–4
 - sample handling 40–1, 42–3
 - specificity/interference 41
 - stability 42–4
 - validation controls 39–40, 41–2
 - variability 44–5
 - whole blood 37–47
- external audits 265
- external quality assurance (EQA) 266–7

- FACS *see* fluorescence-activated cell-sorting (FACS)
- FFPE *see* formalin-fixed, paraffin-embedded (FFPE) tissues
- FITC *see* fluorescein isothiocyanate (FITC)
- fit-for-purpose validation 279–80
- flow cytometry
 - acceptance criteria 100–1
 - accountability 111
 - anticoagulants 76
 - apoptosis 76, 79–81
 - applications 73–81
 - certification 110
 - checklist 114
 - data handling 78–9, 111, 118–19, 121
 - endpoint assays 255–7
 - good laboratory practice 107–13, 116, 124
 - immunophenotyping 74–5
 - implementation 101–2
 - instrumentation 87, 101, 103, 109–10, 120, 122–4
 - intersubject range of marker expression 91, 103
 - intracellular cytokine staining 80, 107–25
 - in *vitro* stimulation 117
 - labeling and staining 77, 78–9, 86–7, 89
 - limits of quantification 122–3
 - lymphocyte activation capacity 194
 - lyophilization 115–16
 - methodology 119–22
 - multimerized MHC molecules 133
 - phospho-specific 80–1
 - precision 98–100, 103, 108
 - reagents 87–91, 103, 110, 113–15, 122–3
 - regulatory bodies 129
 - sample handling 76–7, 91–8, 110–2, 121
 - specificity 77, 87–91
 - stability 76–7, 91–8, 103
 - staining 112, 117–18, 121
 - standardization 108–13, 123–4
 - T-cell surface markers 85–105
 - validation controls 116–22
 - variability 91, 96, 99–100, 103, 111–12
 - whole blood 76–7, 85–105
- fluorescein isothiocyanate (FITC) 51, 60
- fluorescence-activated cell-sorting (FACS) 129, 131
- formalin-fixed, paraffin-embedded (FFPE) tissues 51, 54, 55–6, 59, 61–2
- four-layered assays 4
- freeze/thaw procedures
 - endpoint assays 242
 - enzyme-linked immunospot assays 149–50, 154–66, 178–82
 - ex vivo* stimulation assays 38
 - neutralization bioassays 220–1, 231, 234
 - peripheral blood mononuclear cells 26–7, 29
- GCP *see* good clinical practice (GCP)
- genomics 277–8
- GLP *see* good laboratory practice (GLP)

- good clinical practice (GCP) 263
- good laboratory practice (GLP)
- assay development 2, 9
 - endpoint assays 262–7
 - enzyme-linked immunospot assays 128
 - flow cytometry 102–3, 107–13, 116, 124
 - future directions 277–80
 - immunohistochemistry assays 53–6, 66
 - internal/external audits 265
 - laboratory programs 262–3
 - personnel training 263
 - quality assurance 265–7
 - reagents/equipment 264
 - reporting requirements 264–5
 - see also* standard operating procedures
- heat-induced epitope retrieval (HIER) 59
- heparinized plasma 213–14
- HER2 50, 52, 63, 69
- Herceptin 52–3, 69
- HIER *see* heat-induced epitope retrieval (HIER)
- high throughput screening (HTS) 278
- HIV SELECTEST 246, 249
- HIV/AIDS
- Cylex technology 194
 - endpoint assays 239–75
 - flow cytometry 74, 108
 - humoral immune responses 258–62
 - vaccine pipeline 248–50
- HIV-1 vaccine trials network (HVTN) 241–2, 250
- HLA *see* human leukocyte antigens (HLA)
- HTS *see* high throughput screening (HTS)
- human immunodeficiency virus *see* HIV/AIDS
- human leukocyte antigens (HLA)
- endpoint assays 245
 - enzyme-linked immunospot assays 133, 134
 - flow cytometry 74–5
- humoral immune responses to HIV 1, 258–62
- HVTN *see* HIV-1 vaccine trials network
- ICS *see* intracellular cytokine staining (ICS)
- IHC *see* immunohistochemistry (IHC) assays
- IL-5 ELISPOT assays 173–91
- immune function assays 249
- immunohistochemistry (IHC) assays 49–72
- antibodies 49–51, 57, 59, 61
 - applications 68–72
 - assay development 57–65, 68
 - biomarker scoring 62–4, 67, 69
 - clinical studies 66–72
 - data handling 67
 - detection systems 60
 - fixation 51, 54, 55, 57, 59, 61–2
 - good laboratory practice 53–6, 66
 - labeling and staining 51–2, 54, 59–60, 62–3, 66, 71
 - overview 49–53
 - quality control 65–6
 - quantitative data 64–5
 - rational image analysis 64–5
 - sample handling 55–6
 - sensitivity 61
 - specificity 60, 61–2
 - testing parameters 58, 66
 - tissue selection 58–9
 - validation controls 60
- immunophenotyping 74–5
- interferon- γ
- enzyme-linked immunospot assays 131, 137–8, 143–4, 147–72, 173, 190, 252–3
 - flow cytometry 108, 122–5
 - neutralization bioassays 210, 221–36
- interleukins
- enzyme-linked immunospot assays 147–9
 - flow cytometry 85–6, 88–91, 93–4, 96–102
 - IL-5 ELISPOT assays 173–91
 - neutralization bioassays 210, 215, 221–2, 225, 227–8
- internal audits 265

- intersubject range of marker expression
91, 103
- intracellular cytokine staining (ICS)
enzyme-linked immunospot assays
132, 133
flow cytometry 80, 107–25
HIV/AIDS 252, 255–6, 266–7
- Ki 67, 68
- late activation markers 74–5
- lead in to assay development 2–3
- limits of detection (LOD) 17, 140–1
- limits of quantification (LOQ)
assay development 7, 17, 33
enzyme-linked immunospot assays
141, 155, 160, 168–9, 187–9
ex vivo stimulation assays 45
flow cytometry 122–3
neutralization bioassays 223–5
- linearity 123, 140, 225
- lipopolysaccharide (LPS) 195–6, 201–2
- LOD *see* limits of detection (LOD)
- LOQ *see* limits of quantification (LOQ)
- lymphoproliferative assays (LPA) 252
- lyophilization 115–16
- MAB *see* monoclonal antibodies (MAB)
- major histocompatibility complex
(MHC) 278–9
- master banks 2–3
- matrix effects
assay development 14–15, 20–1
neutralization bioassays 226, 230–1
- mean, definition 13
- MHC *see* major histocompatibility
complex (MHC)
- microarrays 278
- monoclonal antibodies (MAB) 4,
115, 119
- MS *see* multiple sclerosis (MS)
- multi-layered assays 4
- multimerized MHC molecules 133
- multiple sclerosis (MS) 174
- multiplex analysis 39, 42
- NAbs *see* neutralizing antibodies (Nabs)
- NAT *see* nucleic acid tests (NAT)
- natural killer (NK) cells 210, 221–2
- neutral buffered formalin (NBF) 51,
54, 55
- neutralization bioassays 209–37
acceptance criteria 235–6
anti-drug antibodies 209–10
cell passage number 233
clinical samples 236
critical reagents 218–19, 234
culture time 234
cut-off 213–14, 215, 231–2
cytokine interference 225
dilutional linearity 225
dose response curves 227–30
drug interference 216–17, 232
enzyme-linked immunoassay 210,
223–7, 235
freeze/thaw procedures 220–1, 231,
234
HIV/AIDS 259–62
induction assays 227–33
interferon- γ 210, 221–36
limits of quantification 223–5
matrix effects 226, 230–1
methodology 212–13, 222–3
precision 226, 232–3
quality control 227, 235
robustness 217, 233–5
ruggedness 217
sample handling 212, 215, 219–21
sensitivity 214–15, 232
specificity 215–17, 231
stability 219–21, 226, 234–5
standard curves 223–5
tumor necrosis factor 210, 211–21,
225
validation controls 211–12, 215, 217,
219–22, 228–31, 235
variability 217–19, 226, 232–3
- neutralizing antibodies (NAbs)
assay development 2, 4–5
endpoint assays 259–62
neutralization bioassays 210, 215,
221, 222–3, 227–36
- NHS *see* normal human serum (NHS)
- NIAID–CANVAC study 108
- NK *see* natural killer (NK) cells
- normal human serum (NHS)
212–14, 231
- nucleic acid tests (NAT) 243, 245, 249

- one-layered assays 4
- optimal conditions 27, 40
- optimization 13–15
 - Cylex technology 197–8
 - enzyme-linked immunospot assays 134–8, 176–8
 - ex vivo* stimulation assays 40–3
 - peripheral blood mononuclear cells 28–31
- p24 gag 260–2
- p53 50
- PAbs *see* polyclonal antibodies (PAbs)
- PBLs *see* peripheral blood lymphocytes (PBLs)
- PBMCs *see* peripheral blood mononuclear cells (PBMCs)
- PBS *see* phosphate buffered saline (PBS)
- pentamer analysis 133
- perforin (PFN) 137
- peripheral blood lymphocytes (PBLs) 88–90
- peripheral blood mononuclear cells (PBMCs)
 - acceptance criteria 34
 - anticoagulants 30–1, 32
 - antigen-specific T cell immunity assays 26–7
 - assay development 28–31
 - cell density 29
 - clinical studies 35
 - conditions 30
 - data handling 34
 - definitions 27–8
 - endpoint assays 241–2, 252, 254, 256, 259
 - enzyme-linked immunospot assays 29, 133–4, 139, 148–70, 174–87, 189–90
 - flow cytometry 80, 108, 116–17, 122
 - freeze/thaw procedures 26–7, 29
 - isolation 28–9
 - limits of quantification 33
 - optimization 28–31
 - robustness 33
 - sample handling 32
 - specificity/interference 30
 - stability 31, 32
 - validation controls 27, 31
 - variability 32–3
- PFN *see* perforin (PFN)
- PHA-P *see* phytohemagglutinin-P (PHA-P)
- phosphate buffered saline (PBS) 51
- phospho-specific flow cytometry 80–1
- phytohemagglutinin-P (PHA-P)
 - Cylex technology 195–6, 197–8, 200, 205
 - IFN- γ ELISPOT assays 148, 150, 153–70
 - IL-5 ELISPOT assays 175–6, 189
- PMA-ionomycin
 - IFN- γ ELISPOT assays 148, 150, 168–70
 - IL-5 ELISPOT assays 175–87, 189
- polychromatic flow cytometry 255–7
- polyclonal antibodies (PAbs) 230, 232–3
- precision
 - assay development 7, 16, 21–2
 - Cylex technology 199–203, 204
 - enzyme-linked immunospot assays 139, 163–6, 182–5, 190
 - ex vivo* stimulation assays 44–5
 - flow cytometry 98–100, 103, 108
 - neutralization bioassays 226, 232–3
 - see also* variability
- predose controls 27, 40
- proliferation assays
 - assay development 2, 3
 - lymphocyte activation capacity 194
- pseudoviruses (PSVs) 260–2
- psoriasis 69–70, 86
- PSVs *see* pseudoviruses
- quadrant markers 78
- qualification experiments 138, 142
- qualitative data, definition 13
- quality assurance 109–11, 128, 265–7
- quality control
 - endpoint assays 243–4
 - enzyme-linked immunospot assays 128, 151, 153
 - immunohistochemistry assays 65–6
 - neutralization bioassays 227, 235
 - samples 39

- quantitative data
 - definition 12
 - immunohistochemistry assays 64–5
 - see also* limits of quantification
- range 141
- rational image analysis 64–5
- reference samples 127–46
- relative standard deviation (RSD) 143–4
- reporting requirements 264–5
- reproducibility *see* variability
- robustness
 - assay development 8
 - ex vivo* stimulation assays 43–4
 - neutralization bioassays 217, 233–5
 - peripheral blood mononuclear cells 33
- RSD *see* relative standard deviation
- ruggedness 217
- safety testing 243
- sample analytes 12
- sample handling
 - assay development 5, 17–19
 - Cylex technology 195, 198–200, 206–7
 - endpoint assays 242
 - enzyme-linked immunospot assays 149–50, 152–66, 178–82
 - ex vivo* stimulation assays 40–1, 42–3
 - flow cytometry 76–7, 91–8, 110–2, 121
 - immunohistochemistry assays 55–6
 - neutralization bioassays 212, 215, 219–21
 - peripheral blood mononuclear cells 32
 - see also* stability
- sample matrices
 - assay development 14–15, 20–1
 - neutralization bioassays 226, 230–1
- sample specific controls 212, 215, 217, 222, 231
- SDS-PAGE *see* sodium dodecyl sulfate poly-acrylamide gel(SDS-PAGE)
- SEA/SEB *see* staphylococcal enterotoxins (SEA/SEB)
- SELECTEST 246, 249
- selectivity 7–8
- semi-quantitative data
 - definition 12
 - immunohistochemistry assays 64–5
- sensitivity
 - immunohistochemistry assays 61
 - neutralization bioassays 214–15, 232
- sodium dodecyl sulfate poly-acrylamide gel (SDS-PAGE) 244
- sodium heparin 241–2
- SOPs *see* standard operating procedures
- specificity
 - assay development 7–8, 16, 19–21
 - Cylex technology 203, 205
 - enzyme-linked immunospot assays 139–40, 152–4, 175–6, 190
 - ex vivo* stimulation assays 41
 - flow cytometry 77, 87–91
 - immunohistochemistry assays 60, 61–2
 - neutralization bioassays 215–17, 231
 - peripheral blood mononuclear cells 30
- stability
 - assay development 8, 15–19
 - Cylex technology 197–9
 - enzyme-linked immunospot assays 162–3, 168, 178, 181
 - ex vivo* stimulation assays 42–4
 - flow cytometry 76–7, 91–8, 103
 - neutralization bioassays 219–21, 226, 234–5
 - peripheral blood mononuclear cells 31, 32
- standard curves
 - assay development 3
 - Cylex technology 197
 - neutralization bioassays 223–5
 - performance 15–17, 23
- standard deviation, definitions 13, 143–4
- standard operating procedures (SOPs)
 - assay development 22
 - Cylex technology 197
 - endpoint assays 263–6
 - enzyme-linked immunospot assays 128
 - flow cytometry 109
 - immunohistochemistry assays 52, 55–6, 62, 65–7

- Staphylococcal enterotoxins (SEA/SEB)
 - Cylex technology 195–6, 201–2
 - enzyme-linked immunospot assays 148, 169–70, 175
- targeted drug therapy 69, 71
- tetramer analysis 133, 252–3
- T-lymphocytes
 - Cylex technology 193–4
 - endpoint assays 251–8
 - enzyme-linked immunospot assays 129, 133, 147–9, 173–4
 - flow cytometry 74–5, 85–105
 - good laboratory practice 278–9
- tumor necrosis factor (TNF) 210, 211–21, 225
- TUNEL assays 79
- two-layered assays 4
- vaccine pipeline 248–50
- validation controls 6–8
 - assay development 13, 15–16, 20
 - enzyme-linked immunospot assays 152–66
 - ex vivo* stimulation assays 39–40, 41–2
 - flow cytometry 116–22
 - immunohistochemistry assays 60
 - neutralization bioassays 211–12, 215, 217, 219–22, 228–31, 235
 - peripheral blood mononuclear cells 27, 31
 - validation plans 5–8
 - validation reports 8, 14, 16
 - variability
 - assay development 21–2
 - Cylex technology 199–203, 204
 - endpoint assays 262, 264
 - enzyme-linked immunospot assays 134–8, 142, 161–2, 163–6, 182–5, 190
 - ex vivo* stimulation assays 44–5
 - flow cytometry 91, 96, 98–100, 103, 111–12
 - neutralization bioassays 217–19, 226, 232–3
 - peripheral blood mononuclear cells 32–3
 - viability 180–1
- Western blot analyzes 243, 244–6, 247–9
- whole blood (WB)
 - ex vivo* stimulation assays 37–47
 - flow cytometry 76–7, 85–105

